公开(公告)号：WO2012033792A2

公开(公告)日：2012-03-15

申请号：PCT/US2011/050618

申请日：2011-09-07

Applicant: DMI ACQUISITION CORP. ,  BAR-OR, David

Inventor： BAR-OR, David

IPC: A61K31/496

CPC classification number: A61K38/12 ,  A61K31/495 ,  A61K31/496 ,  A61K38/05 ,  Y10T428/13

Abstract: The invention provides (i) a method of treating metabolic syndrome in an animal, (ii) a method of suppressing the appetite of an animal, (iii) a method of treating obesity in an animal, (iv) a method of reducing the weight of an animal in need thereof, (v) a method of reducing a blood lipid level in an animal in need thereof, (vi) a method of treating non¬ alcoholic steatohepatitis in an animal, and (vii) a method of inhibiting adipogenesis. The methods comprise administering an effective amount of an active ingredient, wherein the active ingredient comprises a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them to the animal. The invention also provides a kit comprising a container holding a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them; and instructions for administration of the diketopiperazine, the prodrug or the pharmaceutically-acceptable salt according to a method of the invention. The diketopiperazines have the formula given in the application.

Abstract translation: 本发明提供（i）一种治疗动物代谢综合征的方法，（ii）抑制动物食欲的方法，（iii）治疗动物肥胖的方法，（iv）减轻体重的方法 （v）降低有需要的动物血脂水平的方法，（vi）在动物中治疗非酒精性脂肪性肝炎的方法，和（vii）抑制脂肪生成的方法。 所述方法包括施用有效量的活性成分，其中活性成分包含二酮哌嗪，二酮哌嗪的前药或它们中任一种的药学上可接受的盐对动物。 本发明还提供了一种试剂盒，其包含容纳二酮哌嗪的容器，二酮哌嗪的前体药物或其任一种的药学上可接受的盐; 以及根据本发明的方法施用二酮哌嗪，前药或药学上可接受的盐的说明书。 二酮哌嗪类具有本申请中给出的公式。

公开(公告)号：WO2010151530A1

公开(公告)日：2010-12-29

申请号：PCT/US2010/039458

申请日：2010-06-22

Applicant: DMI ACQUISITION CORP. ,  BAR-OR, David

Inventor： BAR-OR, David

IPC: A61K31/58

CPC classification number: A61K31/58 ,  A61K9/0053

Abstract: The invention provides a method of inhibiting vascular hyperpermeability in an animal in need thereof. The method comprises administering a vascular- hyperpermeability-inhibiting amount of a danazol compound to the animal. The invention also provides a method of modulating the cytoskeleton of an endothelial cell in an animal. The method comprises administering an effective amount of a danazol compound to the animal.

Abstract translation: 本发明提供了抑制有需要的动物血管高渗透性的方法。 该方法包括向动物施用抑制血管渗透压的量的达那唑化合物。 本发明还提供调节动物内皮细胞的细胞骨架的方法。 该方法包括向动物施用有效量的达那唑化合物。

公开(公告)号：WO2012033792A3

公开(公告)日：2012-06-07

申请号：PCT/US2011050618

申请日：2011-09-07

Applicant: DMI ACQUISITION CORP ,  BAR-OR DAVID

Inventor： BAR-OR DAVID

IPC: A61K31/497 ,  A61K31/4965

CPC classification number: A61K38/12 ,  A61K31/495 ,  A61K31/496 ,  A61K38/05 ,  Y10T428/13

Abstract: The invention provides (i) a method of treating metabolic syndrome in an animal, (ii) a method of suppressing the appetite of an animal (Hi) a method of treating obesity in an animal, (iv) a method of reducing the weight of an animal in need thereof, (v) a method of reducing a blood lipid level in an animal in need thereof, (vi) a method of treating nonalcoholic steatohepatitis in an animal, and (vii) a method of inhibiting adipogenesis. The methods comprise administering an effective amount of an active ingredient, wherein the active ingredient comprises a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them to the animal.

Abstract translation: 本发明提供（i）一种治疗动物代谢综合征的方法，（ii）抑制动物食欲的方法（Hi）一种治疗动物肥胖症的方法，（iv）减轻动物体重的方法 （v）降低有需要的动物的血脂水平的方法，（vi）在动物中治疗非酒精性脂肪性肝炎的方法，和（vii）抑制脂肪形成的方法。 所述方法包括施用有效量的活性成分，其中活性成分包含二酮哌嗪，二酮哌嗪的前药或它们中任一种的药学上可接受的盐对动物。

公开(公告)号：WO2012033789A2

公开(公告)日：2012-03-15

申请号：PCT/US2011/050612

申请日：2011-09-07

Applicant: DMI ACQUISITION CORP. ,  BAR-OR, David

Inventor： BAR-OR, David

IPC: A61K38/12 ,  A61P9/10 ,  A61P27/02 ,  A61P17/00 ,  A61P11/00 ,  A61P9/12 ,  A61P25/00 ,  A61P13/12 ,  B65D69/00

CPC classification number: A61K31/496

Abstract: The invention provides a method of inhibiting vascular hyperpermeability in an animal in need thereof. The method comprises administering an effective amount of a diketopiperazme, a prodrug of a diketopiperazme or a pharmaceutically-acceptable salt of either of them to the animal, wherein the diketopiperazme has the formula set forth in the specification. The invention also provides a method of modulating the cytoskeleton of an endothelial cell in an animal. The method comprises administering an effective amount of a diketopiperazme, a prodrug of a diketopiperazme or a pharmaceutically-acceptable salt of either of them to the animal, wherein the diketopiperazme has the formula set forth in the specification. The invention further provides a kit. The kit comprises a diketopiperazme, a prodrug of a diketopiperazme or a pharmaceutically-acceptable salt of either of them to the animal, wherein the diketopiperazme has the formula set forth in the specification.

Abstract translation: 本发明提供了抑制有需要的动物血管渗透性过高的方法。 该方法包括给动物施用有效量的二酮哌嗪，二酮哌嗪或其中任一种的药学上可接受的盐的前药，其中二酮哌嗪具有在说明书中提出的通式。 本发明还提供了调节动物内皮细胞的细胞骨架的方法。 该方法包括给动物施用有效量的二酮哌嗪，二酮哌嗪或其中任一种的药学上可接受的盐的前药，其中二酮哌嗪具有在说明书中提出的通式。 本发明还提供了一种试剂盒。 试剂盒包含二酮哌嗪，二酮哌嗪或其中任一种的药学上可接受的盐与动物的前药，其中二酮哌嗪具有在说明书中列出的通式。

公开(公告)号：WO2012033789A3

公开(公告)日：2012-05-31

申请号：PCT/US2011050612

申请日：2011-09-07

Applicant: DMI ACQUISITION CORP ,  BAR-OR DAVID

Inventor： BAR-OR DAVID

IPC: A61K38/12 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P13/12 ,  A61P17/00 ,  A61P25/00 ,  A61P27/02 ,  B65D69/00

CPC classification number: A61K31/496

Abstract: The invention provides a method of inhibiting vascular hyperpermeability in an animal in need thereof. The method comprises administering an effective amount of a diketopiperazme, a prodrug of a diketopiperazme or a pharmaceutically-acceptable salt of either of them to the animal, wherein the diketopiperazme has the formula set forth in the specification. The invention also provides a method of modulating the cytoskeleton of an endothelial cell in an animal. The method comprises administering an effective amount of a diketopiperazme, a prodrug of a diketopiperazme or a pharmaceutically-acceptable salt of either of them to the animal, wherein the diketopiperazme has the formula set forth in the specification. The invention further provides a kit. The kit comprises a diketopiperazme, a prodrug of a diketopiperazme or a pharmaceutically-acceptable salt of either of them to the animal, wherein the diketopiperazme has the formula set forth in the specification.

Abstract translation: 本发明提供了抑制有需要的动物血管高渗透性的方法。 该方法包括向动物施用有效量的二酮哌啶，二酮哌嗪或其药学上可接受的盐的前药，其中二酮哌啶具有本说明书中阐述的式。 本发明还提供调节动物内皮细胞的细胞骨架的方法。 该方法包括向动物施用有效量的二酮哌啶，二酮哌嗪或其药学上可接受的盐的前药，其中二酮哌啶具有本说明书中阐述的式。 本发明还提供一种试剂盒。 试剂盒包括二酮哌啶，二酮哌嗪的前药或它们中任一种的药学上可接受的盐，其中二酮哌啶具有本说明书中阐述的式。